BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Montaño A, Forero-Castro M, Marchena-Mendoza D, Benito R, Hernández-Rivas JM. New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update. Cancers (Basel) 2018;10:E110. [PMID: 29642462 DOI: 10.3390/cancers10040110] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Castañeda-Partida L, Ocadiz-Delgado R, Sánchez-López JM, García-Villa E, Peñaloza-González JG, Velázquez-Aviña MM, Torres-Nava JR, Martín-Trejo JA, Solís-Labastida K, Guerra-Castillo FX, Bekker-Méndez VC, Rosales-García VH, Romero-Rodríguez D, Mojica-Espinoza R, Mendez-Tenorio A, Ramírez-Calzada CA, Álvarez-Ríos E, Mejía-Aranguré JM, Gariglio P. Global expression profiling of CD10 + /CD19 + pre-B lymphoblasts from Hispanic B-ALL patients correlates with comparative TARGET database analysis. Discov Oncol 2022;13:28. [PMID: 35445848 DOI: 10.1007/s12672-022-00480-7] [Reference Citation Analysis]
2 Naji P, Khatami M, Heidari MM, Hashemi A, Jenabzadeh A, Chamani R, Khanjarpanah Z. Mutational Analysis of theVPREB1Gene of Pre-BCR Complex in a Cohort of Sporadic Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol 2022. [PMID: 35398858 DOI: 10.1097/MPH.0000000000002456] [Reference Citation Analysis]
3 Kośmider K, Karska K, Kozakiewicz A, Lejman M, Zawitkowska J. Overcoming Steroid Resistance in Pediatric Acute Lymphoblastic Leukemia-The State-of-the-Art Knowledge and Future Prospects. Int J Mol Sci 2022;23:3795. [PMID: 35409154 DOI: 10.3390/ijms23073795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wang W, Lyu C, Wang F, Wang C, Wu F, Li X, Gan S. Identification of Potential Signatures and Their Functions for Acute Lymphoblastic Leukemia: A Study Based on the Cancer Genome Atlas. Front Genet 2021;12:656042. [PMID: 34295352 DOI: 10.3389/fgene.2021.656042] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
5 Shin SY, Lee H, Lee ST, Choi JR, Jung CW, Koo HH, Kim SH. Recurrent somatic mutations and low germline predisposition mutations in Korean ALL patients. Sci Rep 2021;11:8893. [PMID: 33903686 DOI: 10.1038/s41598-021-88449-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Moreno Lorenzana D, Juárez Velázquez MDR, Reyes León A, Martínez Anaya D, Hernández Monterde A, Salas Labadía C, Navarrete Meneses MDP, Zapata Tarrés M, Juárez Villegas L, Jarquín Ramírez B, Cárdenas Cardós R, Herrera Almanza M, Paredes Aguilera R, Pérez Vera P. CRLF2 and IKZF1 abnormalities in Mexican children with acute lymphoblastic leukemia and recurrent gene fusions: exploring surrogate markers of signaling pathways. J Pathol Clin Res 2021;7:410-21. [PMID: 33890726 DOI: 10.1002/cjp2.211] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 Fang-Fang Z, You Y, Wen-Jun L. Progress in research on childhood T-cell acute lymphocytic leukemia, Notch1 signaling pathway, and its inhibitors: A review. Bosn J Basic Med Sci 2021;21:136-44. [PMID: 32415821 DOI: 10.17305/bjbms.2020.4687] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Mshaik R, Simonet J, Georgievski A, Jamal L, Bechoua S, Ballerini P, Bellaye PS, Mlamla Z, Pais de Barros JP, Geissler A, Francin PJ, Girodon F, Garrido C, Quéré R. HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias. Blood Cancer J 2021;11:61. [PMID: 33737511 DOI: 10.1038/s41408-021-00450-2] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
9 Olivas-Aguirre M, Torres-López L, Pottosin I, Dobrovinskaya O. Overcoming Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: Repurposed Drugs Can Improve the Protocol. Front Oncol 2021;11:617937. [PMID: 33777761 DOI: 10.3389/fonc.2021.617937] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
10 Mroczek A, Zawitkowska J, Kowalczyk J, Lejman M. Comprehensive Overview of Gene Rearrangements in Childhood T-Cell Acute Lymphoblastic Leukaemia. Int J Mol Sci 2021;22:E808. [PMID: 33467425 DOI: 10.3390/ijms22020808] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
11 Lejman M, Włodarczyk M, Styka B, Pastorczak A, Zawitkowska J, Taha J, Sędek Ł, Skonieczka K, Braun M, Haus O, Szczepański T, Młynarski W, Kowalczyk JR. Advantages and Limitations of SNP Array in the Molecular Characterization of Pediatric T-Cell Acute Lymphoblastic Leukemia. Front Oncol 2020;10:1184. [PMID: 32766158 DOI: 10.3389/fonc.2020.01184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Park KJ, Kim IS, Yang EJ, Lim YT, Cho SH. Mutation analysis in Korean patients with T-cell acute lymphoblastic leukemia. Pediatr Hematol Oncol 2020;37:129-39. [PMID: 31852326 DOI: 10.1080/08880018.2019.1701160] [Reference Citation Analysis]
13 Izzo B, Gottardi EM, Errichiello S, Daraio F, Baratè C, Galimberti S. Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches. Front Oncol 2019;9:833. [PMID: 31555590 DOI: 10.3389/fonc.2019.00833] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
14 Tsaouli G, Ferretti E, Bellavia D, Vacca A, Felli MP. Notch/CXCR4 Partnership in Acute Lymphoblastic Leukemia Progression. J Immunol Res 2019;2019:5601396. [PMID: 31346528 DOI: 10.1155/2019/5601396] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
15 Morales-Martinez M, Valencia-Hipolito A, Vega GG, Neri N, Nambo MJ, Alvarado I, Cuadra I, Duran-Padilla MA, Martinez-Maza O, Huerta-Yepez S, Vega MI. Regulation of Krüppel-Like Factor 4 (KLF4) expression through the transcription factor Yin-Yang 1 (YY1) in non-Hodgkin B-cell lymphoma. Oncotarget 2019;10:2173-88. [PMID: 31040909 DOI: 10.18632/oncotarget.26745] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
16 Pavlovic S, Kotur N, Stankovic B, Zukic B, Gasic V, Dokmanovic L. Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment. Genes (Basel) 2019;10:E191. [PMID: 30832275 DOI: 10.3390/genes10030191] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
17 Simioni C, Martelli AM, Zauli G, Melloni E, Neri LM. Targeting mTOR in Acute Lymphoblastic Leukemia. Cells 2019;8:E190. [PMID: 30795552 DOI: 10.3390/cells8020190] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
18 Sanchez VE, Nichols C, Kim HN, Gang EJ, Kim YM. Targeting PI3K Signaling in Acute Lymphoblastic Leukemia. Int J Mol Sci 2019;20:E412. [PMID: 30669372 DOI: 10.3390/ijms20020412] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
19 Li J, Ma X, Liu C, Li H, Zhuang J, Gao C, Zhou C, Liu L, Wang K, Sun C. Exploring the Mechanism of Danshen against Myelofibrosis by Network Pharmacology and Molecular Docking. Evid Based Complement Alternat Med 2018;2018:8363295. [PMID: 30622613 DOI: 10.1155/2018/8363295] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
20 Nitulescu GM, Van De Venter M, Nitulescu G, Ungurianu A, Juzenas P, Peng Q, Olaru OT, Grădinaru D, Tsatsakis A, Tsoukalas D, Spandidos DA, Margina D. The Akt pathway in oncology therapy and beyond (Review). Int J Oncol 2018;53:2319-31. [PMID: 30334567 DOI: 10.3892/ijo.2018.4597] [Cited by in Crossref: 34] [Cited by in F6Publishing: 97] [Article Influence: 8.5] [Reference Citation Analysis]
21 Madrazo E, Ruano D, Abad L, Alonso-Gómez E, Sánchez-Valdepeñas C, González-Murillo Á, Ramírez M, Redondo-Muñoz J. G9a Correlates with VLA-4 Integrin and Influences the Migration of Childhood Acute Lymphoblastic Leukemia Cells. Cancers (Basel) 2018;10:E325. [PMID: 30213075 DOI: 10.3390/cancers10090325] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
22 Evangelisti C, Chiarini F, McCubrey JA, Martelli AM. Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. Int J Mol Sci 2018;19:E1878. [PMID: 29949919 DOI: 10.3390/ijms19071878] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]